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Abstract Recently, increased expression of interleukin-18 (IL-18) has been shown in sarcoid airwayepithelium. How-
ever, IL-18 expression has not been investigated extensively in bronchoalveolar lavage (BAL) cells in sarcoidosis yet. Ex-
pression of IL-18 and tumournecrosis factor-a (TNFa) mRNAin cells ofthe BALof 23 patientswith sarcoidosis andnine
healthy volunteerswas determined using semiquantitative RT-PCR.IL-18 protein in BAL cellswas investigated by immu-
nocytochemistry (ICC).IL-18 protein levels in BAL cell culture supernatants frompatients and controlswith andwithout
LPS stimulationweremeasured byenzyme-linked immuno-sorbent assay. BAL cells frompatientswere stimulatedwith
either IL-10 or IL-13 and IL-18 proteinlevelswere determined.IL-18mRNAexpressionwas significantlydecreasedin BAL
cells of patients compared to control subjects (1.6270.27 vs.4.2970.77, Po 0.05).TNFamRNAexpressionwas signifi-
cantly increased in BAL cells of patients in comparison to control subjects (0.6370.09 vs. 0.1170.08, Po 0.05). ICC
showedlesspositive alveolarmacrophagesin sarcoidosispatients thanincontrol subjects (26 vs. 53%).IL-18 proteinlevels
didnotdiffer significantlybetweenbothgroups.Stimulationwith IL-10 significantlyreduced IL-18 proteinconcentrationin
sarcoidosis patients.Our results suggest that BAL cells may not be the main source of IL-18 production in sarcoidosis in
vivo. Since IL-18 production of BAL cellswas not impaired in culture antiinflammatory cytokinesmight contribute to de-
creased IL-18 expression in vivo. r2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2003.1477, available online athttp://www.sciencedirect.com
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Sarcoidosis is a systemic granulomatous diseasewith un-
knowncause.The characteristic lesions arenoncaseating
epitheloid granulomas with dominant in¢ltration of
CD4+ lymphocytes andmacrophages (1). Previous inves-
tigations revealed that in£ammation in sarcoidosis is pre-
dominatedbyTh1type cytokines e.g. interleukin-2 (IL-2),
interleukin-12 (IL-12) and interferon-g (IFN-g) (2^5). In-
terleukin-18 (IL-18) is a recently described cytokine
which belongs to the interleukin-1 cytokine family. It
was initially de¢ned as IFN-g inducing factor (6). Subse-
quent studies showed that IL-18 has a broad array of ef-
fector functions implicating IL-18 as an important
regulator of both innate and acquired immunity. IL-18
and IL-12 synergistically stimulate IFN-g production and
enhance NK- and T-cell mediated cytotoxicity (7).
Furthermore, IL-18 induces the di¡erentiation of T pre-Received 22 July 2002, accepted in revised form 4 November 2002
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E-mail address: hans-peter.hauber@mcgill.cacursor cells intoTh1cells.Previous reportshave indicated
that IL-18 is expressed at site of chronicTh1mediated in-
£ammatory diseases e.g. Crohn’s disease or rheumatoid
arthritis (8^10).
In sarcoidosis, elevated protein levels of IL-18 have
been found in bronchoalveolar lavage £uids (BALFs) as
well as in serum (11,12). Increased IL-18mRNA expression
has also been reported in airway epithelium and positive
immunohistochemistry staining for IL-18 in the intersti-
tium of sarcoid lungs (13,11). However, IL-18 expression in
alveolar macrophages has not been investigated exten-
sively although these cells are regarded to play an impor-
tant role in contributing to and maintaining alveolar
in£ammation in sarcoidosis.
In this study,IL-18andtumournecrosis factor-a (TNFa)
mRNA expression in cells of the bronchoalveolar
lavage (BAL) and in peripheral blood mononuclear cells
(PBM) of patients with sarcoidosis was determined. Im-
munostaining of IL-18 protein was used to detect IL-18
protein in BAL cells of patients. Furthermore, IL-18
protein secretion from lipopolysaccharide (LPS)
stimulated and unstimulated BAL cells of patients and
controls was investigated. In order to assess the e¡ect
522 RESPIRATORYMEDICINEof antiin£ammatory cytokines incubation experiments
were performed using recombinant human interleukin-
10 (rhIL-10) and recombinant human interleukin-13 (rhIL-
13).
PATIENTSANDMETHODS
Patients and controls
Twenty-three patients (nine males, 14 females) were in-
vestigated. The diagnosis of sarcoidosis was established
byclinical symptoms, histology and/or cytology, and typi-
cal radiological signs on chest X-rays. Mean age was 44
years ranging from 26 to 75. CD4/CD8 ratio was
4.070.6 (mean7SEM if not otherwise stated). Radiologic
stageswere as follows:13 stage I, seven stage II, and three
stage III. Median level of serum ACE was 49 U/l.Vital ca-
pacity (VC) was 89.772.5% (of predicted), forced ex-
piratory volume in 1s (FEV1) was 84.973.5% (of
predicted), and transfer factor of carbon monoxide for
measurement of di¡usion capacity (TLCO) was
85.373.6% (of predicted). All patients su¡ered from ac-
tive sarcoidosis. Activity was de¢ned by (1) recently de-
veloped or increasing cough or dyspnoea; and/or (2)
systemic symptoms such as cutaneous lesions,weakness,
fever, arthralgia; and/or (3) increasing opacities on chest
radiography according to previously reported criteria of
activity.(5,14)
Nine healthy volunteers with no history of lung dis-
ease served as control subjects (¢ve male, four female).
Mean age was 28 years ranging from 23 to 31. VC was
98.472.1%, FEV1 99.571.2% (of predicted). Table 1 sum-
marises the characteristics of the patients and the con-
trol subjects.
Cell isolation and RNApreparation
Peripheral bloodmononuclear cells (PBM) were isolated
by centrifugation over Ficoll^Paque (Pharmacia, Uppsa-
la, Sweden) and washed twice with PBS containing 2%
fetal calf serum (Seromed, Berlin, Germany). RNAzol
(Wak, Bad Soden, Germany) was added and samples
were stored at 201C until further preparation. RNA
was extracted by treatment with chloroform and preci-
pitatedwith isopropanol.
RT-PCR
RNAwas reverse-transcribed using 2ml 25mM MgCl2,
1ml 10 PCR bu¡er,1ml 10mM of each deoxynucleotide
triphosphate (dNTP), 0.5ml 50mMOligodT, 0.5ml 20U/ml
RNAse inhibitor and 0.5ml 50U/ml reverse transcriptase
(Perkin Elmer Biosystems, Roche, Branchburg, USA).
The mixture was incubated at 421C for 30min and at
991C for 5min. Samples were stored at201Cuntil am-
pli¢cation.The resultant cDNAwas ampli¢ed by PCR in a ther-
mal cycler (Hybaid, Teddington,UK) with a ¢nal volume
of100ml containing10ml cDNA (IL-13, IL-4) or 5ml cDNA
(b-actin),10 or15ml dilution bu¡er, 8ml12mMMgCl2, 8ml
10xPCR bu¡er, 55.5ml H2O with DEPC, 0.5ml 5U/ml re-
combinant Taq DNA polymerase (Perkin Elmer Biosys-
tems, Roche, Branchburg, USA) and 2.0ml 15mmol of
each primer.The oligonucleotide primers for PCRwere
based on publishedmRNA sequences. b-actin served as
control.The human b-actin primers were 50 -GTGGGG
CGC CCC AGG CAC CA-30 for the upstream primer
and 50 -CTCCTTAATGTC ACG CACGAT TTC-30 for
the downstreamprimer; IL-18 utilised 50 -GCT TGA ATC
TAA ATTATC AGT C-30 for the upstream primer and
50 -GAA GAT TCA AAT TGC ATC TTA T-30 for the
downstream primer. TNFa primers were 50 -CAG AGG
GAA GAG TTC CCC AG-30 for the upstream primer
and 50 -CCT TGG TCT GGT AGG AGA CG-30 for the
downstream primer. PCR ampli¢cation for b-actin was
performed for 36 cycles (1min at 941C, 1min at 601C,
40 s at 721C), for 35 cycles (1min at 721C,1min at 901C,
1min at 551C) for IL-18, and for 40 cycles (1min at 941 C,
1min at 601 C, 40 s at 721C) forTNFa.
Identi¢cation of PCRproducts
PCR products were analysed by electrophoresis on a 2%
agarose gel containing ethidium bromide and visualised
by UV light. The sizes of the PCR products were com-
paredwith the expected PCR product length andmole-
cular weightmarkers (Boehringer,Mannheim,Germany).
Densitometric and semiquantitative PCR
analysis
Densitometric analysis was performed by the Eagle Eye
II Still Video Systeme (Stratagene, La Jolla,USA) .The ex-
pression was standardised to that of b-actin expression
from the same reverse-transcribed IL-18 or TNFa sam-
ple. Ratios of cytokine:b-actin were calculated for semi-
quantitative RNA expression measurement as
previously described (15).
Immunocytochemistry (ICC) for IL-18
BAL cells were ¢xed on glass slides and permeabilised
with acetone for 4min. A monoclonal antihuman IL-18
mouse antibody (MAB 318, R&D Systems, Minneapolis,
USA) or isotype control for each sample was added for
1h. After that slides were washed withTris bu¡er con-
taining 10% fetal calf serum (Tris+FCS) and antimouse
rabbit antibody and antirabbit pig antibody were added
for 30min. After washing withTris+FCS for 5min slides
were incubated with alkaline phosphatase antialkaline
phosphatase (APAAP) complex for 30min and washed
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once. Fast red substrate containing 2mg naphthol,
200ml dimethylformamide (DMF), 2.4mg levamisole and
10mg fast red in 9.8ml 0.1M Tris bu¡er was added onto
cells for a maximum of 20min (staining intensity was vi-
sually controlled). After a wash period of 5min with
water cells were counterstained with hemalaun for
2min andwashed for10min. Isotype controls were used
to assess intensity of staining. Two hundred alveolar
macrophages were counted in each sample and the per-
centage rate of positive cells was calculated.
BAL cell culture
BAL cells were cultured in RPMImedium (BiochromKG,
Berlin,Germany) containing10% FCS,1% L-glutamine and
2% penicilline/streptomycine at a temperature of 37.01C.
Atmosphere contained 5.0% CO2. BAL cell cultures of
both patients and controls were incubated for18h with-
out andwith LPS at a concentration of1.0mg/ml. Further-
more rhIL-13 (5.0 ng/ml, R&D Systems, Minneapolis,
USA) or rhIL-10 (0.4mg/ml, Strathmann Biotech GmbH,
Hannover,Germany) were added to BAL cell cultures of
seven patients. Cell culture supernatants for enzyme-
linked immuno-sorbent assay (ELISA) measurements
were obtained by centrifugation and stored at201C.
Interleukin18 enzyme-linked
immunoabsorbent assay
An IL-18 ELISA (R&D Systems, Minneapolis, USA) was
used to determine the concentration of IL-18 protein in
BAL cell culture supernatants of the patient group after
18h of incubationwithout andwith addition of rhIL-10 or
rhIL-13. IL-18 concentrations were determined by com-
parison to recombinant standards run parallel with each
batch of assay.Minimumdetectable dose of IL-18was less
than15pg/ml as indicated by the manufacturer. Concen-
trations less than15pg/mlwere calculated.
Statistics
Expression of IL-18 and TNFa between patients and con-
trol subjectswas comparedbyusing theMann^Whitney
test. Protein concentrations were compared using the
Wilcoxon signed rank test.Correlation was tested using
Pearson’s correlation. A P valueo 0.05 was considered
signi¢cant.
RESULTS
Total and di¡erential cell counts
BAL and PBM total and di¡erential cell counts for both
patients and control subjects are summarised inTable 2.IL-18 and TNFamRNAExpression
IL-18 mRNAwas expressed in all BAL cells and PBM of
both patients and controls (Fig. 1). Semiquantitative
PCR analysis showed that IL-18 expression was signi¢-
cantly decreased in BAL cells of patients in comparison
to controls (1.6270.27 vs. 4.2970.77) (Po 0.05). PBM
of both groups expressed IL-18 mRNA in similar
amounts with mean values of 1.3970.25 in the
patients and 1.5370.56 in the controls (P 4 0.05, Fig. 2
and Table 3).
TNFawas expressed in BAL cells of all but two sarcoi-
dosis patients.BAL cells from only three of seven investi-
gated control subjects showed TNFamRNAexpression.
The mean values of semiquantitative PCR analysis of
TNFa expression were statistically signi¢cant di¡erent
(0.6370.09 in the patient group vs. 0.1170.08 in the con-
trol group;Po 0.05). PBMof13 patients expressed TNFa
mRNAwhereas in the other 10 patients no expression
could be seen (mean value 0.3470.07). In the control
group in PBM from two of ¢ve tested patients TNFa
mRNA could be detected (mean value 0.1770.14). This
di¡erence was not statistically signi¢cant (P 4 0.05,
Fig. 3 and Table 3).
Immunostaining of IL-18 protein in BAL cells
of patients and controls
In order to determine the source of IL-18 production in
BAL cells of11sarcoidosis patients andcontrols, immuno-
cytochemical staining with human IL-18 antibody was
performed using the APAAP technique. Only alveolar
macrophages stained positive (Fig. 4). Counting positive
andnegative (nonstained) alveolarmacrophagesrevealed
a mean rate of 26.473.2% of IL-18 positive macrophages
in patients whereas in the control group the mean rate
of IL-18 positive alveolarmacrophageswas 53.0719.2% (P
o 0.05). Furthermore, a signi¢cant positive correlation
could be observed between semiquantitative RT-PCR
analysis of IL-18 in BAL cells and rate of IL-18 positive al-
veolar macrophages in the patient group (r = 0.81;
Po 0.05, Fig. 5).
IL-18 protein secretion from BAL cells of
patients and controlswith andwithout
stimulationwith LPS
BAL cell cultures were incubated for 18h with or with-
out stimulation of LPS. There was no statistically
signi¢cant di¡erence in IL-18 protein levels in unstimu-
lated cell culture supernatants between tested patients
(1183.087300.92pg/ml; n=15) and tested controls
(1288.697440.38pg/ml; n=4). Stimulation with LPS led
to an increase in IL-18 protein concentrations in both
groups. However, the di¡erence between the patient
group (1817.627637.39pg/ml; n=8) and the control group
(1612.717182.56pg/ml; n=4) was not statistically signi¢-
cant (P4 0.05, Fig. 6).
FIG 1. Expressionof IL-18mRNAin BAL cells and PBMof sarcoidosispatients (A) andcontrols (B).Left sixlanes: a-actin expressionin
BAL cells/PBM pairs ofthree patients (A) or three control subjects (B).Right six lanes: IL-18 expression in BAL cells/PBM pairs of three
patients (A) or three control subjects (B).
FIG 2. Semiquantitative PCR analysis of IL-18 mRNA expres-
sioninpatients andcontrol subjects.Expressionof IL-18 was nor-
malised to a-actin and ratios were calculated. Mean values are
shownbylines. *:Po 0.05 vs. control.
TABLE 1. Patient and control characteristics.
Patients Controls
Number (male/female) 23 (9/14) 9 (5/4)
Mean age (range)* 44 (26^75) 28 (23^31)
Stage (I/II/III) 13/7/3 F
CD/CD8 ratio 4.070.6 n.d.
ACE (U/l)w 49 n.d.
VC (%pred) 89.772.5 98.472.1
FEV1 (%pred) 84.973.5 99.571.2
TLCO (%pred) 85.373.6 n.d.
Mean7SEM; n. d. notdetermined.
*Inyears. wMedian level in serum.
VC, vital capacity; FEV1, forced expiratory volume in 1s;
TLCO, transfer factorof carbonmonoxide.
TABLE 2. BALand PBM total anddi¡erentialcellcounts.
Patients Controls
BAL total cells (perml) 6.270.9  106 4.770.8  106
Alveolar
macrophages (%)*
66.173.6 86.572.3
Lymphocytes (%)* 31.273.6 8.271.2
Neutrophils (%)* 2.171.1 4.571.9
Eosinophils (%)* 0.670.2 0.870.4
PBM total cells (perml) 12.774.5  106 10.472.1  106
Monocytes (%)* 47.976.0 44.173.5
Lymphocytes (%)* 22.474.4 23.275.0
Neutrophils (%)* 28.575.8 32.175.4
Eosinophils (%)* 1.270.4 0.670.3
Mean7SEM.
*percentage oftotal in£ammatorycells.
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on IL-18 protein secretion from BAL cells
BAL cell cultures of sarcoidosis patients were incubated
with either rhIL-10 (n=4) or rhIL-13 (n=6). Cell cultures
without addition of rhIL-10/rhIL-13 were run in parallel
for each patient. After 18h, a signi¢cant decrease in
IL-18 protein levels could be observed in rhIL-10 stimu-
lated compared to unstimulated cell cultures
(618.12748.94pg/ml vs 752.75770.26pg/ml; P o 0.05).
Incubation with rhIL-13 led to slightly decreased IL-18
protein levels (737.387110.59pg/ml;P4 0.05, Fig. 7).
TABLE 3. IL-18 and TNFaexpression.
Patients Controls P
BAL
IL-18 1.6270.27 4.2970.77 o 0.05
TNFa 0.6370.09 0.1170.08 o 0.05
PBM
IL-18 1.3970.25 1.5370.56 n.s.
TNFa 0.3470.07 0.1770.14 n.s.
Mean7SEM; n.s. not signi¢cant.
FIG 3. Semiquantitative PCR analysis of TNFamRNAexpres-
sion in patients and controls subjects. Expression of TNFa was
normalised to a-actin and ratios were calculated. Mean values
are shownbylines. *:Po 0.05 vs control.
FIG 4. ICC of BAL cells. Alveolar macrophages of sarcoidosis
patients stain positive for IL-18.Originalmagni¢cation  200.
FIG 5. Correlation between IL-18 mRNA expression in BAL
cells and percentage of IL-18 positive alveolar macrophages.
Dots indicate individualvalue pairs.
FIG 6. IL-18 protein levels in BAL cell culture supernatants of
patients and controls.Mean values7SEM are shown for patients
and controlswith andwithout stimulationwith LPS.
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In£ammation in the lungs of sarcoidosis patients has
been shown to be predominated byTh1-type cytokines
e.g. IL-1, IL-12, IFN-g and TNF-a (2^4,16). IL-12 and IL-18have important regulatory functions by directing Th0
cells into development of Th1 cells. Until now IL-18
expression and production by BAL cells in sarcoidosis
has not been extensively investigated although these
cells are considered to play an important role in
pathophysiology of this disease.
In our study, we found that IL-18 mRNA expression
was decreased in BAL cells of sarcoidosis patients in
comparison to healthy controls whereas no signi¢cant
di¡erence could be observed in PBM. Previous reports
have shown that IL-18 expression in the airway epithe-
lium is increased in sarcoidosis (13). IL-18 has also been
found in macrophages of sarcoidosis granulomas (11).
Only one report described IL-18 mRNA expression in
alveolar macrophages. However, in that study the
authors did not commenton the amountof IL-18 expres-
sion but one got the impression that the di¡erence be-
tween patients and controls was not high.Many alveolar
FIG 7. IL-18 proteinlevelsin BAL cellculture supernatants after
incubation without and with rhIL-10/rhIL-13. Mean values7SEM
are shownbycolumns. *:Po 0.05 vsunstimulated.
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less IL-18 than those of control individuals (11). In the pre-
sent study, BAL cells were analysed but not isolated al-
veolar macrophages. Nevertheless, this might re£ect
the in vivo situation in which macrophages, lymphocytes,
and other cells act and react. As expected, the propor-
tion of alveolar macrophages was lower in sarcoidosis
than in healthy controls. This might contribute to de-
creased levels of IL-18 mRNA expression in BAL cells
but immunostaining showed more positive alveolar
macrophages in healthy controls than in patients.
Furthermore, the absolute cell counts of alveolarmacro-
phages as determined by multiplying total BAL cell
counts and percentage of alveolar macrophages did not
di¡er signi¢cantly between patients (4.09millions/ml)
and controls (4.05millions/ml) indicating that macro-
phages of sarcoidosis patients really produce less IL-18
than those of controls.We also examined TNFa mRNA
expression which has been shown to be elevated in sar-
coidosis (16). In the present study, TNFa expression was
increased in sarcoidosis patients in comparison to
healthy controls which agrees with previous reports
(16). BAL cells used in the present studymight therefore
not be di¡erent from those used by other investigators.
Neither IL-18 norTNFa expression showed any di¡er-
ence between patients and controls in PBM.This ¢nding
supports the notion that in£ammation in sarcoidosis is
compartimentalised (17).However, Shigehara et al. found
increased IL-18 serumprotein levels in sarcoidosis but no
clear information was given concerning the source of IL-
18 production and secretion in that report (12).
Although mRNA expression indicates that protein
translation should be present in cells it does not prove
protein production and secretion.Therefore, immunos-
taining for IL-18 protein in BAL cells was performed.
Analysis of immunocytochemical staining delineated a
clear positive correlation between IL-18 mRNA expres-
sion levels (by means of semiquantitative RT-PCR) and
percentage rate of IL-18 positive alveolar macrophages.Furthermore, signi¢cantly less IL-18 positive alveolar
macrophageswere observed in patients.These data sup-
port the ¢nding that BAL cells/alveolar macrophages
produce less IL-18 than those of controls. Like previous
authors, we were able to show IL-18 protein in macro-
phages indicating that IL-18 is produced by these cells
(11). IL-18 expressionhas alsobeendemonstratedin tissue
macrophages in granulomatous lesions of muscular sar-
coidosis (18).This ¢ndingdoes notexclude the data ofCa-
meron et al. who found IL-18 expression in airway
epithelium (13). However, it must be taken into account
that BAL cells in sarcoidosis may not be themain source
of IL-18 production and secretion.This might not be sur-
prising because in£ammation in sarcoidosis can be ob-
served in the lung parenchyma as well as in the alveoli.
Greene et al. showed that IL-18 levels were increased in
the epithelial lining £uid of sarcoidosis patients (19). In
that study, the authors also showed that IL-18 might be
involved into CD4+ T lymphocyte activation by enhan-
cing IL-2 gene expression. However, they did not exam-
ine IL-18 expression in BALmacrophages (19).
In order to further investigate IL-18 production and
secretion by BAL cells without in£uence of bronchial
epithelium, cell culture experiments were performed.
IL-18 protein levels in BAL cell culture supernatants after
18h of incubation did not di¡er signi¢cantly between pa-
tients and controls. Addition of LPS exhibited no signi¢-
cant e¡ect. In both groups, IL-18 protein levels increased
after LPS. However, elevation of IL-18 seemed higher in
the patient group than in the control group.This ¢nding
is in agreement with previous studies which reported a
marked increase in sarcoidosis patients (11). The results
also indicate that IL-18 secretion is not impaired in BAL
cells of sarcoidosis patients in vitro but it may also not be
elevated. These data raise the question if there are any
mechanisms, e.g. mediators like antiin£ammatory cyto-
kines that could suppress IL-18 expression and secretion
in BAL cells in sarcoidosis in vivo.
To test whether antiin£ammatory cytokinesmight in-
£uence IL-18 secretion BAL cell cultures of patientswere
incubated with either rhIL-10 or rhIL-13. IL-10 has been
shown to inhibit IL-18 expression (20). Minshall et al.
found a signi¢cant increase of IL-10 mRNA positive cells
in patients with active sarcoidosis (5).Moreover, in a re-
cent studyby Bingisseret al. spontaneous secretion of IL-
10 from alveolar macrophages in sarcoidosis was re-
ported (21). IL-13 has been reported to inhibit TNFa se-
cretion thus acting as an antiin£ammtory cytokine (22).
Investigations in our own laboratory showed IL-13 ex-
pression and secretion in BAL cells from sarcoidosis pa-
tients (unpublished observations). A signi¢cant decrease
of IL-18 protein levels in cell culture supernatants after
18h of incubation with rhIL-10 could be observed
whereas incubationwithrhIL-13 didnot signi¢cantly alter
IL-18 protein levels. Although these ¢ndings indicate that
IL-10 might in£uence IL-18 expression in sarcoidosis, the
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cannot be judged without a dose^response analysis.
Other cytokines might also have an e¡ect. A potential
candidate may be transforming growth factor-a (TGF-
a).Gene transfer of TGF-a DNA in an animal model re-
duced IL-18 (23). Elevated protein levels of TGF-a have
been found in BAL £uid in one study whereas another
study demonstrated increased local secretion of TGF-a
only in patients with altered lung function (24,25). An-
other possibility to explain the decreased IL-18 expres-
sion in BAL cells of sarcoidosis patients might be down
regulation of IL-18 mRNA expression in BAL cells due to
elevated IL-18 protein levels in BAL £uid.This hypothesis
as well as other antiin£ammatory mediators should be
evaluated in future studies.
In conclusion in this study we were able to demon-
strate decreased IL-18 expression in BAL cells of sarcoi-
dosis patients. However, IL-18 protein secretion of BAL
cells with and without LPS stimulation did not di¡er be-
tween patients and controls. IL-10 but not IL-13 had an
inhibitory e¡ect on IL-18 protein secretion in vitro. Ac-
cording to these data, itmust be taken into account that
BAL cells e.g. alveolar macrophages are not the main
source of elevated IL-18 protein levels in BAL £uid found
in sarcoidosis. These ¢ndings suggest that the airway
epithelium and lung parenchyma are important sites of
IL-18 production and secretion in sarcoid in£ammation.
Moreover, antiin£ammatory processes e.g. antiin£am-
matory cytokines or negative feedback mechanisms
seem to be important regulatory mechanisms in order
to prevent an exaggerated in£ammation in sarcoidosis.
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